Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA: brodalumab versus guselkumab after inadequate response to ustekinumab in plaque psoriasis
NL-OMON52789Phase 4Active, not recruiting
- Sponsor
- LEO Pharma
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in plaque psoriasis comparing Brodalumab arm with Guselkumab arm (2 arms). Primary endpoint: PASI 100 response at Week 16. Started Nov 2021; status: active, not recruiting.
02
Drugs
brodalumabguselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON52789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52789.